{"id":"placebo-ambrisentan-matching","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1111","moleculeType":"Small molecule","molecularWeight":"378.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo formulations are used in clinical trials to provide a blinded control arm that matches the active comparator in appearance, taste, and route of administration. This placebo is specifically designed to match ambrisentan (an endothelin receptor antagonist used in pulmonary arterial hypertension) to maintain trial blinding and allow for proper efficacy and safety assessment of the active drug.","oneSentence":"This is a placebo control matching the appearance and administration of ambrisentan, an endothelin receptor antagonist, with no active pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:33.549Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trial of ambrisentan for pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT07245680","phase":"PHASE3","title":"COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-15","conditions":"Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)","enrollment":186},{"nctId":"NCT02999906","phase":"PHASE3","title":"Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2017-10","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT01884675","phase":"PHASE3","title":"Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2013-09","conditions":"Hypertension","enrollment":33},{"nctId":"NCT01902758","phase":"PHASE2, PHASE3","title":"Drug Combination on Exercise Performance at High Altitude","status":"COMPLETED","sponsor":"University of Montana","startDate":"2013-08","conditions":"Acute Mountain Sickness","enrollment":28},{"nctId":"NCT00879229","phase":"PHASE3","title":"ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2009-07","conditions":"Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension","enrollment":40},{"nctId":"NCT00768300","phase":"PHASE3","title":"(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2008-12","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":494},{"nctId":"NCT00617305","phase":"PHASE4","title":"Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-04","conditions":"Pulmonary Arterial Hypertension","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (Ambrisentan-matching)","genericName":"Placebo (Ambrisentan-matching)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control matching the appearance and administration of ambrisentan, an endothelin receptor antagonist, with no active pharmacological effect. Used for Control arm in phase 3 clinical trial of ambrisentan for pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}